Showing 1101-1110 of 1634 results for "".
- Sciton Consumer Sweepstakes Underwayhttps://modernaesthetics.com/news/sciton-consumer-sweepstakes-underway/2472216/Sciton's nation-wide sweepstakes in which consumers can win $1,000 towards treatment with Sciton devices runs through August 23. Winners will receive $1,000 toward one of several Sciton treatments including
- Neothetics, Inc.'s Stock Tumbles Following "Unambiguous" Negative LIPO-202 Resultshttps://modernaesthetics.com/news/neothetics-incs-stock-tumbles-following-unambiguous-negative-lipo-202-results/2472217/Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial. Neothetics Inc. shares d
- Read Their Lips: Avoid Unnatural Lip Enhancement Results With This Datahttps://modernaesthetics.com/news/read-their-lips-avoid-unnatural-lip-enhancement-results-with-this-data/2472247/Many a Real Housewife from Bravo’s hit reality TV franchise have been chastised for trout pout – or an overfilled, unnatural looking pucker. And now a new study, published by JAMA Facial
- Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefit in Phase 4 Studieshttps://modernaesthetics.com/news/restylane-refyne-and-restylane-defyne-show-lasting-natural-benefit-in-phase-4-studies/2472251/Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that naturalness in facial expressions was at least main
- Juvéderm Vollure XC FDA Approved for Correction of Facial Wrinkles and Foldshttps://modernaesthetics.com/news/juvderm-vollure-xc-fda-approved-for-correction-of-facial-wrinkles-and-folds/2472255/The FDA has approved Allergan plc's Juvéderm Vollure XC for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21. In the US pivotal clinical trial, a majority (59 percent) of subjects saw improvement in moderate to severe na
- BTL Aesthetics Unveils New Ultra Femme 360° Technology for Vaginal Rejuvenationhttps://modernaesthetics.com/news/btl-aesthetics-unveils-new-ultra-femme-360-technology-for-vaginal-rejuvenation/2472265/BTL Industries is introducing its new 360° technology to leading cosmetic dermatologists and physicians during the annual American Academy of Dermatology (AAD) Conference taking place in Orlando, FL, March 3rd – 7th, with th
- Deadline Extended for Medical Spa State of the Industry Statistical Studyhttps://modernaesthetics.com/news/deadline-extended-for-medical-spa-state-of-the-industry-statistical-study/2472272/The American Med Spa Association (AmSpa) has extended the deadline for the 2017 Medical Spa St
- AAFPRS Forecasts Regeneration, Precision, and Personalization as Defining Aesthetic Trends for 2026https://modernaesthetics.com/news/aafprs-forecasts-regeneration-precision-and-personalization-as-defining-aesthetic-trends-for-2026/2484425/Aesthetic medicine is rapidly evolving beyond enhancement and rejuvenation, moving toward regenerative, precision-driven care tailored to the individual. The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) has released its annual aesthetic trend forecast, highlighting the t
- Facial Aesthetic Surgical Training May Lag Behind Market Demand, Study Findshttps://modernaesthetics.com/news/facial-aesthetic-surgical-training-may-lag-behind-market-demand-study-finds/2484290/A new analysis published in the Journal of Plastic, Reconstructive & Aesthetic Surgery suggests that US plastic surgery residency programs may not be fully aligned with procedural trends in the growing facial aesthetics market. The study compares Accreditation Council for Graduate Me
- FDA Clears AVAVA Device for Wrinkle Treatment Across All Skin Typeshttps://modernaesthetics.com/news/fda-clears-avava-device-for-wrinkle-treatment-across-all-skin-types/2484238/AVAVA® has received US Food and Drug Administration (FDA) clearance for the treatment of fine lines and wrinkles across Fitzpatrick skin types I-VI, marking its second clearance in recent months following its prior approval for acne scars. The nonablative platform, powered by Focal Point T